AKT3 and gastric adenocarcinoma: Using the AKT antagonist ipatasertib or overexpressing miR-181a-5p had comparable effects to MALAT-1 knockdown, highlighting the significance of the MALAT-1/miR-181a-5p/AKT3 axis in the development of gastric adenocarcinoma [103].